Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP4 | P15090 | 9/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.55 |
| ▸ | PKLR | P30613 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11576786 | 0.80 | FABP4 (0.47) | FABP4ALDH1A1TBXA2RL3MBTL1MAPK1 | |
| SCHEMBL625167 | 0.79 | FABP4 (0.49) | FABP4ALDH1A1MAPK1 | |
| SCHEMBL625386 | 0.78 | CYP3A4 (0.54) | FABP4ALDH1A1LMNATHRBMAPK1 | |
| SCHEMBL9871736 | 0.77 | TBXA2R (0.75) | FABP4ALDH1A1TBXA2RLMNA | |
| SCHEMBL9870095 | 0.77 | TBXA2R (0.75) | FABP4ALDH1A1TBXA2RLMNA | |
| SCHEMBL9870233 | 0.77 | TBXA2R (0.75) | FABP4ALDH1A1TBXA2RLMNA | |
| SCHEMBL9869922 | 0.77 | TBXA2R (0.75) | FABP4ALDH1A1TBXA2RLMNA | |
| SCHEMBL9872413 | 0.77 | TBXA2R (0.75) | FABP4ALDH1A1TBXA2RLMNA | |
| SCHEMBL9879916 | 0.77 | TBXA2R (0.75) | FABP4ALDH1A1TBXA2RLMNA | |
| SCHEMBL9872542 | 0.77 | TBXA2R (0.75) | FABP4ALDH1A1TBXA2RLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8119633-B2 | N-{2-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-2-oxo-ethoxy]-ethyl}-N-ethyl-4-methoxy-2,3,6-trimethyl-phenylsulfonamide; condensing the N-carboxyalkyl phenylsulfonamide with the substituted piperidine; bradykinin receptor antagonists; analgesics; antidiabetics; angiogenesis inhibitors; rheumatic diseases | GRUENENTHAL GMBH (DE) | 2012-02-21 | — | — | US | disclosed |
| EP-2150530-A1 | SUBSTITUTED SULFONAMIDE DERIVATIVES | Grünenthal GmbH (DE) | 2010-02-10 | — | — | EP | disclosed |
| US-20080312231-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2008-12-18 | — | — | US | disclosed |
| WO-2008131947-A1 | SUBSTITUTED SULFONAMIDE DERIVATIVES | Grünenthal GmbH (DE) | 2008-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312231-A1 | Substituted Sulfonamide Compounds | SULT2A1, SULT1A1, SCN1A | FABP4 1511/4885ALDH1A1 511/4885TBXA2R 189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.